Conference Abstracts | 2020
Stradella A; Johnson M; Goel S; Chandana SR; Galsky MD; Calvo E; Moreno V; Park H; Arkenau T; Cervantes A; Farinas-Madrid L; Mileshkin L; Fu S; Plummer R; Evans J; Horvath L; Prawira A; Qu K; Pelham R; Barve MA,
2020,
'Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ)', in
ANNALS OF ONCOLOGY,
ELSEVIER,
ELECTR NETWORK,
Vol. 31,
pp. S465 - S466, presented at
ESMO Virtual Congress,
ELECTR NETWORK,
19 September 2020 - 18 October 2020,
http://dx.doi.org/10.1016/j.annonc.2020.08.644